Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals' stock price has experienced significant positive movement in the past six months, with a 97.42% gain and a 52-week high of $86.31 USD on February 5, 2026. Over the past year, the stock has increased by 156.23%. Key events impacting the stock include a Q3 2025 earnings beat, positive analyst sentiment and price target increases, and product approvals and pipeline progress.

There is no explicit information available indicating demand seasonality for Ionis Pharmaceuticals, Inc.'s products and services. The company's focus on developing treatments for serious and rare diseases suggests that demand may be driven more by disease prevalence and treatment efficacy rather than seasonal patterns.

Ionis Pharmaceuticals, Inc. is a biotechnology company specializing in RNA-targeted medicines, including antisense therapy, RNA interference, and CRISPR therapeutics. Founded in 1989 and headquartered in Carlsbad, California, the company operates within the healthcare sector, focusing on treatments for serious diseases in neurology, cardiometabolic disease, genetic diseases, and rare diseases. Ionis Pharmaceuticals has several major products, including Spinraza, Tegsedi, Waylivra, Qalsody, Wainua, Tryngolza, and Dawnzera.

Ionis Pharmaceuticals, Inc. is based in Carlsbad, California, U.S. The company's products have a global reach, with medicines approved and marketed in the U.S. and Europe. Waylivra was launched in Europe in 2019, and Dawnzera received approval in the European Union in January 2026.

Ionis Pharmaceuticals has maintained a strong brand reputation over the past year, driven by its pioneering work in RNA-targeted medicines and its commitment to addressing serious diseases. The company's reputation is bolstered by its robust pipeline, strategic partnerships, and successful commercialization efforts. Key events that have positively affected Ionis Pharmaceuticals' reputation include new product launches and approvals, positive clinical trial results, and analyst confidence.

Ionis Pharmaceuticals, Inc. is a publicly traded company on Nasdaq (IONS), with ownership distributed among institutional investors, individual shareholders, and company insiders. Institutional investors hold a substantial portion of the company's shares. Major institutional owners include Fmr Llc, Vanguard Group Inc, T. Rowe Price Investment Management, Inc., Capital World Investors, BlackRock, Inc., Wellington Management Group Llp, Bellevue Group AG, BNP Paribas Asset Management Holding S.A., Bank of New York Mellon Corp, and Oppenheimer Asset Management Inc.